Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 31, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share ownership changes rather than a financial performance report.
Material Changes
The filing details a specific change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on January 27, 2006:
- Previous Holdings: 18,075,774 Ordinary Share ADRs
- New Holdings: 18,046,998 Ordinary Share ADRs
- Net Change: Decrease of 28,776 ADRs
- Average Price: $51.11
Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in these shares as beneficiaries of the discretionary fund, alongside other employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R (1) (b) regarding director and connected person transactions.
Key Facts for Investor Verification
- Verify the impact of the 28,776 ADR reduction in the US Retirement Savings Plan on overall insider ownership percentages.
- Confirm the specific roles of Dr. J P Garnier and Dr. T Yamada as beneficiaries of the Plan.
- Note that this filing does not contain operational or financial performance data for the period.